Tumour Markers CA 19-9 and CA 50 in Digestive Tract Malignancies

References

• Koprowski H, Herlyn M, Steplewski Z, et al. Colorectal carcinoma antigens detected by hybridoma antibodies. Somat Cell Genet 1979; 5: 957–972
   PubMedGoogle Scholar
• Magnani J L, Nilsson B, Brockhaus M, et al. A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopentaose. II. J Biol Chem 1982; 257: 14365–14369
   PubMed Web of Science ®Google Scholar
• Lindholm L, Holmgren J, Svennerholm L, et al. Monoclonal antibodies against gastrointestinal tumour-associated antigens isolated as monosialogangliosides. Int Arch Allergy Appl Immunol 1983; 71: 178–181
   PubMedGoogle Scholar
• Månsson J E, Fredman P, Nilsson O, Lindholm L, Holmgren J, Svennerholm L. Chemical structure of carcinoma ganglioside antigens defined by monoclonal antibody C-50 and some allied gangliosides of human pancreatic adenocarcinoma. Biochim Biophys Acta 1985; 834: 110–117
   PubMed Web of Science ®Google Scholar
• Nilsson O, Månsson J E, Lindholm L, Holmgren J, Svennerholm L. Sialosyllactotetraosylceramide, a novel ganglioside antigen detected in human carcinomas by a monoclonal antibody. FEBS Lett 1985; 182: 398–402
   PubMed Web of Science ®Google Scholar
• Nilsson O, Lindholm L, Persson B, . Tissue distribution and concentration of a monoclonal antibody defined tumor-associated ganglioside antigen. Glycoconjugates. Proceedings of 7th International Symposium. Lund-Symposium Secretariat. 1983, M A Chester, D Heinegård, A Lundblad, S Svensson, et al. Lund University, 852–853
   Google Scholar
• Magnani J L, Steplewski Z, Koprowski H, Ginsburg V. Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19–9 in the sera of patients as a mucin. Cancer Res 1983; 43: 5489–5492
   PubMed Web of Science ®Google Scholar
• Jalanko H, Kuuscla P, Roberts P, Sipponen P, Haglund C, Makela O. Comparison of a new tumour marker, CA 19–9, with alpha-fetoprotein and carcinoembryonic antigen in patients with upper gastrointestinal diseases. J Clin Pathol 1984; 37: 218–222
   PubMed Web of Science ®Google Scholar
• Jalanko H, Haglund C, Roberts P J, Kuusela P. Tumor markers in gastrointestinal cancers. Tumor marker antigen, J Holmgren. Studentlitteratur, Lund 1985; 114–122
   Google Scholar
• Ritts R E, Del Villano B C, Jr, Go V LW, Herberman R B, Klug T L, Zurawski V R, Jr. Initial clinical evaluation of an immunoradiometric assay for CA 19–9 using the NCI scrum bank. Int J Cancer 1984; 33: 339–345
   PubMed Web of Science ®Google Scholar
• Chan S H, Lindholm L, Wong L, Oon C J. Tumor markers in hepatocellular carcinoma in Singaporean Chinese. Tumor markers antigens, J Holmgren. Studentlitteratur, Lund 1985; 106–113
   Google Scholar
• Habib N A, Hershman M J, Haberland F, Papp L, Wood C B, Williamson R CN. The use of CA-50 radioimmunoassay in differentiating benign and malignant pancreatic disease. Br J Cancer 1986; 53: 697–699
   PubMedGoogle Scholar
• Habib N A, Hershman M J, Kelly S B, Taylor G, Williamson R CN, Wood C B. Clinical experience with CA-50 in the scrum of carcinoma patients. Eur J Surg Oncol 1989; 15: 361–366
   PubMedGoogle Scholar
• Haglund C, Kuusela P, Jalanko H, Roberts P J. Serum CA50 as a tumor marker in pancreatic cancer: a comparison with CA19–9. Int J Cancer 1987; 39: 477–481
   PubMed Web of Science ®Google Scholar
• Kuusela P, Jalanko H, Roberts P, et al. Comparison of CA 19–9 and carcinoembryonic antigen (CEA) levels in the scrum of patients with colorectal diseases. Br J Cancer 1984; 49: 135–139
   PubMed Web of Science ®Google Scholar
• Kuusela P, Haglund C, Roberts P J, Jalanko H. Comparison of CA-50, a new tumour marker, with carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP) in patients with gastrointestinal diseases. Br J Cancer 1987; 55: 673–676
   PubMed Web of Science ®Google Scholar
• Benini L, Cavallini G, Zordan D, et al. A clinical evaluation of monoclonal (CA 19–9, CA 50, CA 12–5) and polyclonal (CEA, TPA) antibody-defined antigens for the diagnosis of pancreatic cancer. Pancreas 1988; 3: 61–66
   PubMed Web of Science ®Google Scholar
• Paganuzzi M, Onetto M, Marroni P, et al. CA 19–9 and CA 50 in benign and malignant pancreatic and biliary diseases. Cancer 1988; 61: 2100–2108
   PubMed Web of Science ®Google Scholar
• Metz C E. Basic principles of ROC analysis. Semin Nucl Med 1978; 8: 283–298
   PubMed Web of Science ®Google Scholar
• Del Villano B C, Brennan S, Brock P, et al. Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA-19–9. Clin Chem 1983; 29: 549–552
   PubMed Web of Science ®Google Scholar
• Holmgren J, Lindholm L, Persson B, et al. Detection by monoclonal antibody of carbohydrate antigen CA 50 in serum of patients with carcinoma. Br Med J 1984; 288: 1479–1482
   PubMed Web of Science ®Google Scholar
• Lindholm L, Johansson C, Jansson E L, Hallberg C, Nilsson O. An immunoradiometric assay (IRMA) for the CA-50 antigen. Tumor marker antigen, J Holmgren. Studentlitteratur, Lund 1985; 123–133
   Google Scholar
• Masson P, Pålsson Andr B., Én-Sandberg Å. CA-50 in patients with pancreatic disease—an evaluation of three different laboratory techniques. Scand J Clin Lab Invest 1988; 48: 751–755
   PubMed Web of Science ®Google Scholar
• Masson P, Pålsson B, Andrén-Sandberg Å. Cancer-associated tumour markers CA 19–9 and CA-50 in patients with pancreatic cancer with special reference to the Lewis blood cell status. Br J Cancer 1990; 62: 118–121
   PubMedGoogle Scholar
• Jalanko H. Alpha-fetoprotein in cancer. Ann Chir Gynaecol 1989; 78: 27–31
   PubMedGoogle Scholar
• Haglund C, Roberts P J, Kuusela P, Scheinin T M, Mäkelä O, Jalanko H. Evaluation of CA 19–9 as a serum tumour marker in pancreatic cancer. Br J Cancer 1986; 53: 197–202
   PubMedGoogle Scholar
• Steinberg W M, Gelfand R, Anderson K K, et al. Comparison of the sensitivity and specificity of the CA19–9 and carcinoembryonic antigen assays in detecting cancer of the pancreas. Gastroenterology 1986; 90: 343–349
   PubMed Web of Science ®Google Scholar
• Haglund C, Roberts P J, Järvinen H, Pyrhönen S, Kuusela P. CA 19–9 in postoperative monitoring of radically operated patients with pancreatic cancer. Pankreas i Fokus, N Thorsgaard, N Ebbehöj. Meda AS, Herlev 1989; Vol. V: 87–96
   Google Scholar
• Ashwell G, Harford J. Carbohydrate-specific receptors of the liver. Ann Rev Biochem 1982; 51: 531–554
   PubMed Web of Science ®Google Scholar